- ORITAVANCIN
-
-
2026-05-24
- CAS:171099-57-3
- Min. Order:
- Purity: 0.99
- Supply Ability:
- ORITAVANCIN
-
- $5.00/ KG
-
2026-04-10
- CAS:171099-57-3
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
Related articles - What is Oritavancin?
- Oritavancin is a second-generation lipoglycopeptide antibiotic derived from modifications of chloroeremomycin, a naturally occ....
- Mar 10，2022
|
| | ORITAVANCIN Basic information |
| Product Name: | ORITAVANCIN | | Synonyms: | ORITAVANCIN;Oritavancin (LY333328);(4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin;(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]vancomycin;LY 333328;Orbactiv;Oritavancin (Lyophilized Powder For IV Infusion);rideoxy-3-methyl-α-L-arabino-hexopyranosyl)-β-D-g | | CAS: | 171099-57-3 | | MF: | C86H97Cl3N10O26 | | MW: | 1793.1 | | EINECS: | | | Product Categories: | | | Mol File: | 171099-57-3.mol |  |
| | ORITAVANCIN Chemical Properties |
| density | 1.59±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 2.93±0.70(Predicted) |
| | ORITAVANCIN Usage And Synthesis |
| Definition | ChEBI: A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. | | Clinical Use | Antibacterial agent | | Enzyme inhibitor | This novel, semi-synthetic glycopeptide antibiotic (FW = 1793.10 g/mol; CAS 171099-57-3), also known as LY333328, Orbactiv, and (4R)-22-O- (3-amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(pchlorophenyl) benzyl)vancomycin, disrupts the cell membrane of Grampositive bacteria and inhibits both transglycosylation and transpeptidation. Oritavancin differs from vancomycin by the presence of a hydrophobic N-4-(4-chlorophenyl)benzyl substituent on the disaccharide, the addition of a 4-epi-vancosamine monosaccharide to the amino acid residue in Ring-6, and replacement of the vancosamine moiety by 4-epi-vancosamine. When compared vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillinresistant methicillinresistant Staphylococcus aureus, LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Indeed, a single infusion of this antibiotic (1200 mg) can clear serious bacterial skin infections, including methicillin-resistant Staphylococcus aureus, or MRSA, as effectively as the usual 7-10 day, twice-daily regimen of vancomycin now needed to treat patients. | | Drug interactions | Potentially hazardous interactions with other drugs
Anticoagulants: possibly increases warfarin
concentration. | | Metabolism | In vitro human liver microsome studies indicated that
oritavancin is not metabolised. It is excreted unchanged;
less than 1% and 5% of a dose is recovered in the urine
and the faeces. |
| | ORITAVANCIN Preparation Products And Raw materials |
|